Price controls in Colombia could hurt market growth; Drug shortages in U.K. taking toll;

@FiercePharma: FDA Grants Astellas Qualified Infectious Disease Product Designation for Isavuconazole. Release | Follow @FiercePharma

@EricPFierce: Takeda tries on outsider for CEO. Forest tees up cuts. GSK's Witty heads to China. Read it in FiercePharma. More | Follow @EricPFierce

@CarlyHFierce: ICYMI in FierceBiomarkers: Protein C4d linked to higher mortality rates in lung cancer patients. Story | Follow @CarlyHFierce

> New price controls in Colombia could threaten growth in the Latin American market. Story

> A new lawsuit has been filed in Washington to prevent drug take-back requirements there. Story

> India is dismissing a committee set up nearly 6 years ago to work out a method for lowering the prices of patented drugs. Story

> A new report from the Royal Pharmaceutical Society in the U.K. says that up to 700,000 patients a year are being hurt by drug shortages. Story  

> The FDA has issued a warning that the anti-seizure drug Onfi (clobazam) can cause rare but serious skin reactions that can result in permanent harm and death. Warning

Medical Device News

@FierceMedDev: Volcano green-lights a $200M share buyback under M&A pressure. News | Follow @FierceMedDev

@MarkHFierce: Inogen joins a select group of med device companies that have filed IPO plans this year. Article | Follow @MarkHFierce

@MichaelGFierce: Check out FierceBiotech's Top Women in Biotech 2013. More | Follow @MichaelGFierce

@GalenMoore: Xlumena brings in hedge fund Third Point for a $25M Series C aimed at FDA approval. Story | Follow @GalenMoore

> 23andMe pulls ads after FDA warning, but sales roll on. More

> Medtronic unveils a $14M surgical training facility in Florida. Item

Biotech News

@FierceBiotech: Xencor Prices Initial Public Offering. Release | Follow @FierceBiotech

@JohnCFierce: Sanofi is touting U300 PhIII diabetes data. Important program for the co. Release (PDF) | Follow @JohnCFierce

@DamianFierce: Kinda disappointed Celgene couldn't get more arcane clauses into this OncoMed deal. Story | Follow @DamianFierce

@EmilyMFierce: Male contraceptive breakthrough: Australian, UK researchers collaborate on protein discovery. More | Follow @EmilyMFierce

> Sanofi touts promising PhIII data on next-gen diabetes therapy as rivals circle. Story

> Angel investors ante up $9M to fuel Blaze's early-stage program for 'tumor paint'. Report

> Novo CEO claims 'strong' pipeline effort will boost sales. Item

Pharma Manufacturing News

> Irish plant shutdown move puts another Merck site on the block. More

> Wockhardt braces for lost sales after FDA bans its main plant. Story

> Gland Pharma targets U.S. injectables sector after securing $200M. Article

> India drops plans to limit foreign ownership of production capacity. News

> FDA outlines plans for new compounding pharmacy powers. Report

> Hedge fund ups the ante in game of chicken with McKesson. Item

Biotech Research News

> NIH announces $100M for new HIV research initiative. Story

> Key hep C protein revealed, paving the way for new vaccines. News

> Novartis team IDs new malaria target. Article

> NIH publishes first Alzheimer's genomics data for researchers. Report

> Male contraceptive breakthrough: Australian, UK researchers collaborate on protein discovery. More

> Study: Standardization needed for drug screening studies. Item

And Finally... Consumers in Australia are paying 14 times more for their prescription drugs than patients in New Zealand, Canada and the U.K., adding perhaps $1 billion a year to their expenses. Story

Suggested Articles

Novartis said it plans to use the complete response rate data for a U.S. filing in follicular lymphoma in 2021.

Sen. Elizabeth Warren asked the SEC to probe Kodak trades made before the Trump administration unveiled their drug supply deal—and $765M in funding.

Amarin's wild 2020 ride continues with plans to launch its cardiovascular med Vascepa in Europe without a bigger marketing partner.